RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

516 Episodes

  1. Connecting Rare Disease Patients in India and the United States

    Published: 2/6/2019
  2. Regenerative Medicine Moves into the Spotlight

    Published: 1/30/2019
  3. Learning New Tricks from Pathogenic Bacteria to Target the Microbiome

    Published: 1/24/2019
  4. Orphan Drug Accelerator Spin-Out Tackles Rare Endocrine Disorders

    Published: 1/16/2019
  5. Aspa Therapeutics Forges Gene Therapy for Rare Neurological Condition

    Published: 1/9/2019
  6. How Patient-Led Collaborations Are Transforming Rare Disease Drug Discovery and Development

    Published: 1/2/2019
  7. Sobi Expands Its Immunology Franchise with HLH Drug Approval

    Published: 12/27/2018
  8. Learning to Thrive

    Published: 12/19/2018
  9. Late-Stage Trial Underway for Treatment of Rare Obesity Disorder

    Published: 12/12/2018
  10. RegenxBio Bets Its Gene Therapy Technology Provides Competitive Edge

    Published: 12/5/2018
  11. The Potential for Digital Health Technologies to Transform Clinical Trials

    Published: 11/28/2018
  12. Matching Volunteers to Rare Disease Organizations in Need

    Published: 11/21/2018
  13. How One Rare Disease Organization Used Technology to Provide Greater Patient Insight to FDA

    Published: 11/14/2018
  14. The Potentially Deadly Consequences of an Oversight in Newborn Screening Tests

    Published: 11/7/2018
  15. Advancing a New Approach to Sickle Cell Disease

    Published: 10/31/2018
  16. Conquering Life with a Rare Disease

    Published: 10/24/2018
  17. Why Rare Disease Drug Developers Need Regular Interaction with the FDA

    Published: 10/17/2018
  18. Making the Case for an FDA Rare Disease Center of Excellence

    Published: 10/10/2018
  19. An Elite Runner Makes a Cross-Canada Trek for His Son and Rare Disease

    Published: 10/3/2018
  20. How Rare Disease Advocates Can Get The Most out of Collaborations

    Published: 9/26/2018

16 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.